Australia's Epsilon Healthcare climbs on clinical trial supply agreement

Epsilon Healthcare

09/06/2021 02:14

** Shares of medical cannabis developer  EPN.AX  rise as
much as 6.5% to A$0.165, biggest intraday pct gain since June 1 
    **  Co says it is supplying a clinical study with
cannabidiol medicines to treat severe behavioural problems in
youth with intellectual disability  urn:newsml:reuters.com:*:nASX819zXY
    ** Says trial, to be conducted over two years, is taking
place at Murdoch Children's Research Institute in Victoria 
    ** Co will receive a royalty-free licence to study data
generated from the trial - EPN
    ** Stock down ~34% this year, as of last close 

 (Reporting by Tejaswi Marthi in Bengaluru)
 ((tejaswi.marthi@thomsonreuters.com))